Anacor Pharmaceuticals Announces Late-Breaking Oral Presentation of Crisaborole Topical Ointment, 2% Phase 3 Pivotal Data at the 74th Annual Meeting of the American Academy of Dermatology

PALO ALTO, Calif.--()--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that data from its Phase 3 pivotal studies of investigational drug crisaborole topical ointment, 2% will be presented at the 74th Annual Meeting of the American Academy of Dermatology in Washington, D.C. “Crisaborole Topical Ointment, 2%: a Novel, Nonsteroidal, Topical Anti-Inflammatory, Phosphodiesterase 4 Inhibitor: Results from Two Phase 3 Studies Treating Children and Adult Patients with Mild to Moderate Atopic Dermatitis” was accepted as a late-breaking abstract for oral presentation on Saturday, March 5, 2016 at 10:12 a.m., in Room 146C.

“Crisaborole Topical Ointment, 2%: a Novel, Nonsteroidal, Topical Anti-Inflammatory, Phosphodiesterase 4 Inhibitor: Results from Two Phase 3 Studies Treating Children and Adult Patients with Mild to Moderate Atopic Dermatitis”

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor’s first approved drug, KERYDIN® (tavaborole) topical solution, 5%, is an oxaborole antifungal approved by the U.S. Food and Drug Administration in July 2014 for the topical treatment of onychomycosis of the toenails. In July 2014, Anacor entered into an exclusive agreement with Sandoz Inc., a Novartis company, pursuant to which PharmaDerm, the branded dermatology division of Sandoz, distributes and commercializes KERYDIN in the United States. In September 2014, PharmaDerm launched KERYDIN in the United States. Anacor’s lead product development candidate is crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis and psoriasis. Beyond KERYDIN and crisaborole, Anacor has discovered three investigational compounds that it has out-licensed for further development. The first compound is licensed to Eli Lilly and Company for the potential treatment of an animal health indication. The second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative for the potential treatment of human African trypanosomiasis. The third compound is licensed to GlaxoSmithKline LLC for development in tuberculosis. Anacor also has a pipeline of other internally discovered topical and systemic boron-based compounds in early stages of research and development. These include AN3365, an investigational Gram-negative antibiotic, and certain other wholly-owned investigational product candidates. For more information, visit www.anacor.com.

Contacts

Anacor Pharmaceuticals, Inc.
DeDe Sheel, 650-543-7575
Senior Director, Investor Relations and Corporate Communications

Anacor Pharmaceuticals, Inc.